Mable | Neurolytic Healthcare

Mable | Neurolytic Healthcare, founded in 2019 in the United States, focuses on uncovering the genetic link to migraines. The company's slogan "Uncover the link between your genetics and migraine to help prevent your migraine in advance" underscores its mission. Migraines are known to be heritable, and Mable aims to leverage genetics to prevent migraines and facilitate medication delivery. The startup recently secured a Pre Seed Round investment on 27 July 2022, with support from prominent investors including Y Combinator and the illumina accelerator program. This backing not only provides financial resources but also signifies the industry's confidence in Mable's potential to make a significant impact in the healthcare sector. With its innovative approach, Mable is positioned to address a pressing health issue and improve the lives of individuals affected by migraines.